Trial Profile

Phase 1b Dose Expansion Study of NXC-201 for the Treatment of Patients with Relapsed or Refractory AL Amyloidosis

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 23 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

11 Jul 2025 According to an Immix Biopharma media release, the company is on a track for first Biologics License Application (BLA) submission to FDA,supported by data from this trial.
07 Jul 2025 According to an Immix Biopharma media release, a webcast of the Company's Key Opinion Leader (KOL) event was held on 3 June 2025, to discuss the NXC-201 ASCO 2025 interim results.
07 Jul 2025 According to an Immix Biopharma media release, for the progress of this clinical trial, number of site are increased to include 18 clinical trial sites in US. The trial is moving faster than expected and additional new sites further accelerate the path to BLA submission for FDA approval.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com